BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34881847)

  • 1. Theragnostics in primary and secondary liver tumors: the need for a personalized approach.
    Filippi L; Braat AJ
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):353-370. PubMed ID: 34881847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nuclear medicine techniques for selective internal radiotherapy of liver cancer].
    Staanum PF; Arveschoug AK; Kramer SM; Nielsen JE; Nielsen DT; Ott P; Grønbæk H; Villadsen GE
    Ugeskr Laeger; 2017 Jan; 179(1):. PubMed ID: 28074772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients.
    Sancho L; Rodriguez-Fraile M; Bilbao JI; Beorlegui Arteta C; Iñarrairaegui M; Moran V; Sangro B
    J Vasc Interv Radiol; 2017 Nov; 28(11):1536-1542. PubMed ID: 28916345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical solutions to ensure safe yttrium-90 radioembolization in patients with initial extrahepatic deposition of (99m)technetium-albumin macroaggregates.
    Barentsz MW; Vente MA; Lam MG; Smits ML; Nijsen JF; Seinstra BA; Rosenbaum CE; Verkooijen HM; Zonnenberg BA; Van den Bosch MA
    Cardiovasc Intervent Radiol; 2011 Oct; 34(5):1074-9. PubMed ID: 21191588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation With Treatment Efficacy.
    Song YS; Paeng JC; Kim HC; Chung JW; Cheon GJ; Chung JK; Lee DS; Kang KW
    Medicine (Baltimore); 2015 Jun; 94(23):e945. PubMed ID: 26061323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
    Lau WY; Kennedy AS; Kim YH; Lai HK; Lee RC; Leung TW; Liu CS; Salem R; Sangro B; Shuter B; Wang SC
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):401-7. PubMed ID: 20950954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates.
    Brosch J; Gosewisch A; Kaiser L; Seidensticker M; Ricke J; Zellmer J; Bartenstein P; Ziegler S; Ilhan H; Todica A; Böning G
    Phys Med; 2020 Dec; 80():317-326. PubMed ID: 33248338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.
    Mikell JK; Mahvash A; Siman W; Baladandayuthapani V; Mourtada F; Kappadath SC
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):888-896. PubMed ID: 27623307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors.
    Bilbao JI; Garrastachu P; Herráiz MJ; Rodríguez M; Iñarrairaegui M; Rodríguez J; Hernández C; de la Cuesta AM; Arbizu J; Sangro B
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):523-31. PubMed ID: 19841973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors.
    Sarfaraz M; Kennedy AS; Cao ZJ; Sackett GD; Yu CX; Lodge MA; Murthy R; Line BR; Van Echo DA
    Med Phys; 2003 Feb; 30(2):199-203. PubMed ID: 12607837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.
    Garin E; Rolland Y; Laffont S; Edeline J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):559-75. PubMed ID: 26338177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
    Ahmadzadehfar H; Sabet A; Biermann K; Muckle M; Brockmann H; Kuhl C; Wilhelm K; Biersack HJ; Ezziddin S
    J Nucl Med; 2010 Aug; 51(8):1206-12. PubMed ID: 20660379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography.
    Campbell JM; Wong CO; Muzik O; Marples B; Joiner M; Burmeister J
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):313-20. PubMed ID: 19362251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative comparison of pre-therapy
    Knešaurek K; Tuli A; Pasik SD; Heiba S; Kostakoglu L
    Eur J Radiol; 2018 Dec; 109():57-61. PubMed ID: 30527312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.